Nonresectable Combined Hepatocellular Carcinoma and Cholangiocarcinoma: Analysis of the Response and Prognostic Factors after Transcatheter Arterial Chemoembolization

Abstract

TACE is safe and may be effective for prolonging the survival of patients with nonresectable combined HCC-cholangiocarcinoma, as compared with the historically reported survivals of these patients. Tumor vascularity is highly associated with tumor response. The patient survival period after TACE for combined HCC-cholangiocarcinoma is significantly dependent on tumor size, tumor vascularity, Child-Pugh class, and presence or absence of portal vein invasion.